Qualigen Therapeutics Inc - QLGN Net Assets per Single Share

Qualigen Therapeutics (QLGN) generates revenue through the sale of diagnostic systems and targeted therapies. The book value per share reflects overall asset dynamics, with the indicator currently standing at 0.79. Growth prospects are driven by the development of oncology drugs and early disease detection systems, while the advancement of nanotechnologies and antiviral molecules lays the foundation for a future monopoly and stable rent.

The business model of Qualigen Therapeutics (QLGN) relies on the high scalability of diagnostic systems, where sales growth against fixed costs directly impacts asset capitalization. By analyzing the BVPS chart, an investor can see the real value of ownership, stripped of inflated goodwill and paper revaluations, which allows for an objective assessment of the company's intrinsic value and the risks of sharp intangible asset write-downs.